Elicio Therapeutics
ELTX
30 hedge funds and large institutions have $20.9M invested in Elicio Therapeutics in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.
40,750% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $4K
1,212% more capital inflows, than outflows
Capital inflows: $5.16M | Capital outflows: $394K
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
43% more funds holding
Funds holding: 21 → 30 (+9)
2.66% more ownership
Funds ownership: 9.07% → 11.73% (+2.7%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.5M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.04M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$876K |
| 4 |
Renaissance Technologies
New York
|
+$493K |
| 5 |
Cresset Asset Management
Chicago,
Illinois
|
+$272K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
-$192K |
| 2 |
Quantinno Capital Management
New York
|
-$154K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
-$46.3K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$633 |
| 5 |
SBI Securities
Tokyo,
Japan
|
-$10 |
ELTX Hedge Fund Activity: Q3 2025 in Review
30 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q3 2025, worth a combined $20.9M — up 87% from $11.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ELTX positions and 3 closed out — a net gain of 9 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.5M. The largest seller was CM Management, cutting an estimated $192K.
- 30 institutional investors held Elicio Therapeutics (ELTX) as of Q3 2025, up from 21 in Q2 2025.
- Funds reported $20.9M of Elicio Therapeutics stock for Q3 2025, up 87% quarter-over-quarter.
- 12 funds opened new Elicio Therapeutics positions in Q3 2025 and 3 closed out, a net change of +9 holders.
- The largest Elicio Therapeutics buyer in Q3 2025 was Balyasny Asset Management, an estimated $1.5M added.
- The largest Elicio Therapeutics seller in Q3 2025 was CM Management, an estimated $192K sold.
Based on aggregated 13F filings for Q3 2025.